Replies to post #168917 on Biotech Values

[ciotera]

PI-based regimens are all but obsolete..

That is a premature conclusion, I think. Boosted PIs will hold their ground. They are still the preferred regimen for patients with very high VL and whenever one needs a longer half-life/higher barrier to resistance (unlike Isentress and Atripla which are now obsolete).

[genisi]

GILD—In US market, Stribild is #1 HIV regimen and Complera is #2 regimen in all treatment settings.

True for naïve but Stribild is #5 HIV regimen in all patients.